STOCK TITAN

22nd Century Group (Nasdaq: XXII) Launches Pinnacle VLN® Trial in California, Opening Another Major New State for Reduced-Nicotine Cigarettes 

(Moderate)
(Neutral)
Tags

22nd Century Group (Nasdaq: XXII) launched a Pinnacle VLN® reduced-nicotine cigarette retail trial in California, entering about 60 stores initially.

The launch creates the brand’s first California retail presence and a pathway that, if expanded, could reach 2,000+ additional outlets in one of the nation’s largest, policy‑driven tobacco markets.

VLN® is the first and, according to the company, still the only combustible cigarette FDA-authorized to help reduce nicotine consumption, with claims such as “95% less nicotine” and “Helps reduce your nicotine consumption.”

Loading...
Loading translation...

Positive

  • Initial Pinnacle VLN® launch in approximately 60 California retail stores
  • Opens pathway to potential expansion into 2,000 or more additional California outlets
  • First retail presence for VLN® in one of the largest U.S. tobacco markets
  • California’s strong cessation infrastructure may support reduced-nicotine positioning
  • Only FDA-authorized combustible cigarette platform specifically to help reduce nicotine consumption

Negative

  • None.

News Market Reaction – XXII

-1.84%
3 alerts
-1.84% Session close to close
$2.58M Market Cap
0.0x Rel. Volume

In the May 21 session, XXII declined 1.84%, reflecting a mild negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement extends XXII’s VLN® strategy into California via an initial ~60‑store trial with p...
Analysis

This announcement extends XXII’s VLN® strategy into California via an initial ~60‑store trial with potential expansion to 2,000+ outlets, leveraging FDA authorization and a “95% less nicotine” claim. In context of recent losses and active capital‑raising capacity under a $250,000,000 shelf, investors may watch how quickly California translates into revenue, how MRTP status evolves, and how funding choices affect existing shareholders.

Key Figures

Store trial size: approximately 60 stores Potential expansion outlets: 2,000 or more outlets FDA authorization date: December 2021 +5 more
8 metrics
Store trial size approximately 60 stores Initial California Pinnacle VLN® retail trial
Potential expansion outlets 2,000 or more outlets Pathway for broader California rollout over time
FDA authorization date December 2021 VLN® low nicotine combustible cigarette authorization
Nicotine reduction claim 95% less nicotine FDA‑authorized VLN® product labeling
Current share price $0.61 Pre‑news market context, 2026-05-21
Price vs 52-week high -99.84% Distance from 52-week high of $382.95
Shelf registration size $250,000,000 Form S-3 universal shelf filed 2026-03-31
ATM program size $1,840,000 At‑the‑market offering registered under S-3 shelf

Historical Context

5 past events · Latest: May 18 (Positive)
Pattern 5 events
Date Event Sentiment 24h Move Catalyst
May 18 Product launch Positive +6.6% Launch of Pinnacle Pure across multiple top U.S. national retailers.
May 15 Retail expansion Positive -11.9% Major VLN® retail expansion into nearly 150 metro NY/NJ stores.
May 12 Regulatory update Positive -2.2% FDA filing for VLN® MRTP renewal to preserve reduced‑nicotine claims.
May 07 Earnings report Negative -16.4% Q1 2026 results with net loss and adjusted EBITDA loss alongside low revenues.
May 04 Earnings date Neutral -27.6% Announcement of upcoming Q1 2026 earnings release and webcast schedule.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent VLN and Pinnacle announcements often saw mixed or negative price reactions, while earnings‑related disclosures have drawn notably sharp selloffs.

Recent Company History

Over the past weeks, XXII has focused on scaling its VLN® and Pinnacle platforms, from the Pinnacle Pure launch and a ~150-store New York/New Jersey VLN® expansion to MRTP renewal filings and a Q1 2026 report with $4.1M net revenue and a $3.3M net loss. Despite commercial progress and a goal of 5,000 outlets by end‑2026, several of these updates coincided with sizable share price declines.

Key Terms

modified risk tobacco product, mrtp, cessation, menthol, +1 more
5 terms
modified risk tobacco product regulatory
"FDA’s Modified Risk Tobacco Product (MRTP) authorization process—demonstrated"
A modified risk tobacco product is a tobacco or nicotine product that is marketed with claims it reduces health risks or exposure to harmful substances compared with other tobacco products; such claims are typically subject to regulatory review and approval. For investors, this matters because approved modified-risk status can change consumer demand, legal exposure, labeling requirements and market access—similar to how a government-backed “low-risk” label can alter a product’s sales and liability profile.
mrtp regulatory
"as part of the FDA’s Modified Risk Tobacco Product (MRTP) authorization process"
An MRTP (Modified Risk Tobacco Product) is an official U.S. regulatory designation for a tobacco or nicotine product that a regulator has reviewed and allowed to be marketed as posing lower health risks or reduced exposure to harmful substances. Think of it like an official “lower-risk” label: investors watch MRTP decisions closely because they can open or restrict market access, change legal and marketing rights, and materially affect a product’s sales and a company’s valuation.
cessation medical
"emphasis on reducing nicotine dependence, promoting cessation, and limiting access"
Cessation is the stopping or ending of an activity, operation, payment or process. For investors it signals a material change — for example halt of production, distribution, trading or cash flows — that can affect a company’s revenue, risk profile and valuation; think of it like a factory suddenly switching off, which forces you to reassess how much the business is worth and how risky it has become.
menthol medical
"California’s ban on the retail sale of most flavored tobacco products, including menthol cigarettes"
Menthol is a natural or synthetic organic compound that gives a minty flavor and a cooling sensation, commonly used in products like cigarettes, vaping liquids, cough drops, oral-care items, topical pain relievers, and cosmetics. Investors care because menthol’s demand and pricing are shaped by consumer preferences, regulatory actions (such as bans or restrictions), and supply-chain factors, so changes can affect sales, costs, and legal risk for companies that rely on it.
combustible cigarettes technical
"VLN® low nicotine combustible cigarettes were authorized in December 2021"
A combustible cigarette is a rolled tobacco product that is lit and burned so the user inhales smoke and its chemicals, like burning a small log to produce smoke. It matters to investors because these products face steady regulatory restrictions, taxes, health-related litigation and shifting consumer tastes that can sharply affect sales, profit margins and long-term market viability for companies involved in making, selling or regulating tobacco products.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Initial 60-Store California Entry Extends XXII’s Reduced-Nicotine Rollout Into One of the Nation’s Largest and Most Influential Tobacco Markets, With a Pathway to Broader Expansion 

MOCKSVILLE, N.C., May 21, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced the expansion of Pinnacle VLN® into the state of California through an initial approximately 60-store retail trial, establishing the brand’s first retail presence in the state and opening another strategically important market for the Company’s FDA-authorized reduced-nicotine cigarette platform. 

The California trial marks the third step in a series of recent corporate updates regarding 22nd Century’s VLN® combustible cigarette products rollout strategy and follows the Company’s recent significant momentum under the broader Pinnacle platform. By bringing Pinnacle VLN® into California, 22nd Century is extending the reach of its reduced-nicotine product portfolio into one of the largest, most influential, and most policy-driven tobacco markets in the United States.

As an initial 60-store trial, the California launch is designed to establish Pinnacle VLN®’s first retail foothold in the state, build consumer awareness, evaluate early performance, and create a foundation for potential broader expansion over time that could lead to an additional 2,000 or more outlets. For 22nd Century, the launch represents more than a new-state entry — it is a strategic move into a market where tobacco policy, cessation infrastructure, and public health priorities may increasingly support the relevance of reduced-nicotine products.

Larry Firestone, Chief Executive Officer of 22nd Century Group, said, “For investors, this California launch is significant because it shows that the 22nd Century VLN® products story continues to gain breadth and relevance. We are entering a major new state, establishing a first retail foothold where VLN® does not currently exist, and aligning our flagship reduced-nicotine platform with one of the most progressive tobacco policy environments in the country. We believe that combination strengthens both our growth narrative and our long-term strategic value.”

California stands out nationally for its long-running tobacco control framework and its emphasis on reducing nicotine dependence, promoting cessation, and limiting access to products that sustain addiction. The state has spent decades building one of the most comprehensive tobacco control environments in the country, with a strong policy focus on reducing the availability and appeal of addictive tobacco products while increasing access to quitting support.

California maintains one of the country’s most robust cessation infrastructures. Through programs such as Kick It California, the state offers free, evidence-based support through telephone, text, app, and chat-based cessation services, alongside broader healthcare, pharmacy, and public health initiatives designed to increase quit attempts and reduce tobacco dependence. In that environment, 22nd Century believes Pinnacle VLN® can occupy a differentiated position as a combustible product designed for adult smokers seeking a more intentional smoking experience with dramatically reduced nicotine content.

California’s ban on the retail sale of most flavored tobacco products, including menthol cigarettes, further strengthens the strategic logic of this launch. The menthol ban reflects a forward-thinking and critical piece of legislation aimed at reducing the role of flavors and cooling sensations in sustaining tobacco initiation, product appeal, and nicotine dependence. As more regulators focus on the public health impact of menthol and other characterizing flavors, 22nd Century believes products like VLN® become more relevant in markets moving decisively toward stricter standards and harm-reduction-oriented policy frameworks.

FDA Authorization and Scientific Foundation

22nd Century VLN® low nicotine combustible cigarettes were authorized in December 2021, making them the first and still the only combustible cigarettes authorized by the U.S. Food and Drug Administration specifically to help reduce nicotine consumption.

Decades of independent clinical research and peer-reviewed studies—evaluated as part of the FDA’s Modified Risk Tobacco Product (MRTP) authorization process—demonstrated that reducing nicotine content can decrease nicotine intake, increase quit attempts, and reduce overall exposure to nicotine.

FDA-authorized VLN® claims include:

  • 95% less nicotine”
  • “Helps reduce your nicotine consumption”
  • “Greatly reduces your nicotine consumption”
  • “Helps you smoke less”


About 22nd Century Group, Inc.

22nd Century Group is pioneering the Tobacco Harm Reduction and Nicotine Reduction Movements by enabling smokers to take control of their nicotine consumption.

Our Technology is Tobacco
Our proprietary non-GMO reduced nicotine tobacco plants were developed using our patented technologies that regulate alkaloid biosynthesis activities resulting in a tobacco plant that contains 95% less nicotine than traditional tobacco plants. Our extensive patent portfolio has been developed to ensure that our-high-quality tobacco can be grown commercially at scale. We continue to develop our intellectual property to ensure our ongoing leadership in the tobacco harm reduction movement.

Our Products
We created our flagship product, the VLN® cigarette using our low nicotine tobacco, to give traditional cigarette smokers an authentic and familiar alternative in the form of a combustible cigarette that helps them take control of their nicotine consumption. VLN® cigarettes have 95% less nicotine compared to traditional cigarettes and have been proven to allow consumers to greatly reduce their nicotine consumption.

VLN® and Helps You Smoke Less® are registered trademarks of 22nd Century Limited LLC.
Learn more at xxiicentury.com, on X (formerly Twitter), on LinkedIn, and on YouTube.
Learn more about VLN® at tryvln.com.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements, including but not limited to our full year business outlook. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Forward-looking statements include, but are not limited to, statements regarding (i) our expectations regarding regulatory enforcement, including our ability to receive authorization or approval for new products, and (ii) our financial and operating performance. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 26, 2026. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact
Matt Kreps
Investor Relations
22nd Century Group
investorrelations@xxiicentury.com


FAQ

What did 22nd Century Group (XXII) announce about its Pinnacle VLN® launch in California on May 21, 2026?

22nd Century Group announced an initial Pinnacle VLN® reduced-nicotine cigarette retail trial in about 60 California stores. According to 22nd Century, this marks VLN®’s first retail presence in the state and opens a strategically important new tobacco market.

How many California stores will initially carry Pinnacle VLN® cigarettes from 22nd Century Group (XXII)?

The California launch begins with an initial trial in approximately 60 retail locations. According to 22nd Century, this limited rollout aims to build consumer awareness, evaluate early performance, and establish a foundation for possible expansion into 2,000 or more outlets over time.

What makes 22nd Century Group’s VLN® cigarettes unique from an FDA authorization standpoint for XXII investors?

VLN® low nicotine combustible cigarettes were authorized in December 2021 as the first, and reportedly still the only, combustible cigarettes FDA-authorized to help reduce nicotine consumption. According to 22nd Century, this authorization supports modified-risk claims about significantly reduced nicotine content.

What FDA-authorized claims can 22nd Century Group (XXII) make for its VLN® reduced-nicotine cigarettes?

According to 22nd Century, FDA-authorized VLN® claims include “95% less nicotine,” “Helps reduce your nicotine consumption,” “Greatly reduces your nicotine consumption,” and “Helps you smoke less.” These claims are based on VLN®’s substantially lower nicotine content compared with conventional cigarettes.

How large could the Pinnacle VLN® footprint in California become for 22nd Century Group (XXII)?

The company describes the 60-store trial as a first step toward broader expansion potential. According to 22nd Century, successful performance could support entry into an additional 2,000 or more California outlets, significantly increasing VLN®’s market reach in the state.

Why does 22nd Century Group (XXII) view California as strategically important for Pinnacle VLN® cigarettes?

California combines a large, influential tobacco market with strict tobacco control policies and a strong cessation infrastructure. According to 22nd Century, this policy environment may align well with VLN®’s reduced-nicotine focus and harm-reduction positioning for adult smokers.

How does California’s flavored tobacco and menthol ban relate to 22nd Century Group’s VLN® strategy (XXII)?

California bans retail sales of most flavored tobacco products, including menthol cigarettes. According to 22nd Century, this policy context strengthens the logic of introducing reduced-nicotine VLN® products as regulators increasingly emphasize harm reduction and stricter tobacco standards.